Australia and New Zealand Region
The Eisai EMEA (Europe, Middle East, Africa) region includes many markets including Australia, New Zealand, Austria, Belgium, the Czech Republic/Slovakia, France, Germany, Luxembourg, the Netherlands, the Nordics, Portugal, Russia, Spain and the UK/Ireland. In regions where Eisai EMEA does not have an affiliate, we have entered into partnerships to help relevant patients in these regions access our medicines. Please click on the images below for contact details.
Eisai in the Australia & New Zealand Region
Eisai Australia Pty Ltd & Eisai New Zealand Ltd are affiliates of a global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas and we define our corporate mission as "giving first thought to patients and their families, and to increasing the benefits health care provide".
Existing Drug Pipeline
We have a strong global pipeline, this includes new discoveries (an increasing number in late stage development), acquired molecules and further development of licensed products. Areas of clinical development cover the range of neurodegenerative diseases in Central Nervous System, Oncology and Critical Care/Internal Medicines.
Our Culture
As an organisation with patient support at the forefront of everything we do, working at Eisai is a positive career choice, where we strive to make a difference to the lives of those who may benefit from our products and medicines. Our team at Eisai is diverse, supportive and forward thinking, and go above and beyond what is expected. We work with respect and trust each other's intention to do what's best for our patients and the Organisation.
human health care
Our work at Eisai prioritises patients and their families, through our focus to continually improve the benefits that health care can provide.
We call this human health care, (hhc)
